This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AEE788

Novartis AG

Drug Names(s): AEE788

Description: AEE788 inhibits multiple receptor tyrosine kinases including EGFR, HER2, and VEGFR, which stimulate tumor cell growth and angiogenesis. In preclinical studies, AEE788 showed high target specificity and demonstrated antiproliferative effects against tumor cell lines and in animal models of cancer. AEE788 also exhibited direct antiangiogenic activity.


AEE788 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug